Based on the findings, the researchers signal that family screening following a sentinel case may reap benefits for patients with acute hepatic porphyria (AHP).
Researchers are putting a spotlight on the importance of early diagnosis of acute hepatic porphyria (AHP), signaling that having the diagnosis prior to having an attack may lead to a less severe disease course than patients who go undiagnosed.
Over 15 years, the researchers studied a small group of patients hospitalized with AHP and compared the attacks of patients who had an AHP diagnosis with the attacks of patients who were not diagnosed, finding that patients who were previously diagnosed with AHP had a significantly milder disease course.
“These results emphasize the importance of early diagnosis and family members screening following a sentinel case, since it may prevent severe attacks and provide timely specific therapy to these patients,” posited the researchers.
The milder disease course was determined based on several findings among the 9 patients who had 42 attacks over the course of the study. Diagnosed patients had a drastically lower risk of being admitted to the intensive care unit (3.3% vs 75%). When patients were admitted to the hospital, those who were previously diagnosed were admitted for less than half as long as patients without a diagnosis (5 vs 11 days).
Diagnosed patients were also significantly less likely to have seizures (0% vs 50%), psychiatric symptoms (23.3% vs 66.7%), and severe hyponatremia (16.7% vs 83.3%).
Notably, these findings held up in a simple univariate logistic regression.
AHP attacks—generally beginning with abdominal pain before sometimes progressing to severe life-threatening conditions—are typically treated by withholding aggravating factors, intravenous fluids and glucose administration, analgesics, and in severe cases, intravenous heme therapy.
“The two groups did not differ regarding the heme treatment, but attacks in pre-diagnosed patients were more often treated with narcotic pain management,” reflected the researchers. “This implies that although severe complications were rare in this group, pain intensity, an important factor that influences therapeutic decisions, was not mild. The fact that both groups had the same percentage of heme treatment, while the previously undiagnosed patients had given more severe course, and the reason is not fully understood in this study.”
On top of being treated with narcotic pain management more often, patients who were previously diagnosed with AHP also more frequently received glucose, suggesting that the diagnosis facilitated both early and better symptomatic treatment of disease.
Reference
Edel Y, Mamet R, Cohen S, Shepshelovich D, Levi A, Sagy I. The clinical importance of early acute hepatic porphyria diagnosis: a national cohort. Intern Emerg Med. 2021;16:133-139.
Researchers Highlight Clinical Features of AHP, Emergence of siRNA-Based Therapies
February 18th 2021A group of researchers discuss the clinical features and diagnosis of acute hepatic porphyrias (AHP) as well as their take on the approval of the first small interfering RNA (siRNA)-based therapy for the treatment of these patients.
Read More
Review Highlights Diagnostic Approaches, Treatment for ATTR
January 23rd 2021In a review published in Therapeutics and Clinical Risk Management, researchers outlined the current understanding of the transthyretin amyloidosis (ATTR) disease process, diagnostic and surveillance approaches, treatment modalities, and potential future directions.
Read More
Gastrointestinal Issues Prominent Among Patients With Hereditary ATTRv Amyloidosis
January 20th 2021A stark 82% of assessed patients with hereditary transthyretin (ATTRv) amyloidosis exhibited at least 1 gastrointestinal symptom, warranting the need for gastroenterologists in multidisciplinary management of the disease.
Read More